Sponsor

Novartis

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Novartis appears in 631 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials631
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisNCT06395909 · lead sponsor · 2023-04-23
COMPLETED
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple SclerosisNCT06644638 · lead sponsor · 2023-02-15
COMPLETED
A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple SclerosisNCT06588387 · lead sponsor · 2022-11-03
COMPLETED
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesNCT06526000 · lead sponsor · 2022-10-11
COMPLETED
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT06671314 · lead sponsor · 2022-06-02
COMPLETED
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibNCT06705504 · lead sponsor · 2021-06-11
COMPLETED
Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying TherapiesNCT06459232 · lead sponsor · 2020-11-19
COMPLETED
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL StudyNCT06463626 · lead sponsor · 2020-04-06
COMPLETED
Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® BirchNCT01902992 · lead sponsor · 2012-03-01
COMPLETED
Long Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramNCT01281657 · lead sponsor · 2011-02-01
COMPLETED
Real-world Aliskiren Use in Diabetic PatientsNCT01393860 · lead sponsor · 2010-12-01
COMPLETED
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideNCT01233622 · lead sponsor · 2010-10-01
COMPLETED
Phase 4 Study in the Elderly Patients With T2DMNCT01238978 · lead sponsor · 2010-10-01
COMPLETED
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionNCT01237223 · lead sponsor · 2010-10-01
COMPLETED
Zoledronic Acid in MS-patients With OsteoporosisNCT01166178 · lead sponsor · 2010-10-01
TERMINATED
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes MellitusNCT01224366 · lead sponsor · 2010-09-01
COMPLETED
Switching to Iloperidone From Other Antipsychotics in SchizophreniaNCT01207414 · lead sponsor · 2010-08-01
COMPLETED
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)NCT01199861 · lead sponsor · 2010-08-01
COMPLETED
Glycemic Holter Study (Continuous Glucose Monitoring) -NCT01193296 · lead sponsor · 2010-06-01
COMPLETED
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive PatientsNCT01167153 · lead sponsor · 2010-05-01
COMPLETED
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsNCT01127750 · lead sponsor · 2010-05-01
COMPLETED
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus AmlodipineNCT01113047 · lead sponsor · 2010-05-01
COMPLETED
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)NCT01196546 · lead sponsor · 2010-03-01
COMPLETED
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaNCT01092065 · lead sponsor · 2010-03-01
COMPLETED
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesNCT01068860 · lead sponsor · 2010-02-01
COMPLETED
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.NCT01056731 · lead sponsor · 2010-02-01
COMPLETED
Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)NCT01160094 · lead sponsor · 2010-02-01
COMPLETED
12-week Efficacy of IndacaterolNCT01072448 · lead sponsor · 2010-01-01
COMPLETED
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 WeeksNCT01068600 · lead sponsor · 2010-01-01
COMPLETED
Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HypertensionNCT01070030 · lead sponsor · 2010-01-01
COMPLETED
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT01023685 · lead sponsor · 2009-12-01
COMPLETED
Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy PainNCT01089855 · lead sponsor · 2009-12-01
COMPLETED
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive PatientsNCT01042392 · lead sponsor · 2009-11-01
COMPLETED
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus PlaceboNCT01005901 · lead sponsor · 2009-10-01
COMPLETED
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential HypertensionNCT01001572 · lead sponsor · 2009-09-01
COMPLETED
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT00956410 · lead sponsor · 2009-09-01
COMPLETED
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseNCT00986414 · lead sponsor · 2009-09-01
COMPLETED
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44NCT00948766 · lead sponsor · 2009-07-01
COMPLETED
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic HypertensionNCT00931710 · lead sponsor · 2009-07-01
COMPLETED
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic HypertensionNCT00942994 · lead sponsor · 2009-06-01
COMPLETED
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan AloneNCT01070043 · lead sponsor · 2009-06-01
COMPLETED
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)NCT00929110 · lead sponsor · 2009-06-01
COMPLETED
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusNCT00927394 · lead sponsor · 2009-05-01
COMPLETED
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic PatientsNCT00900146 · lead sponsor · 2009-04-01
TERMINATED
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of AgeNCT00834041 · lead sponsor · 2009-04-01
COMPLETED
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment WithdrawalNCT00865020 · lead sponsor · 2009-03-01
COMPLETED
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsNCT00888004 · lead sponsor · 2009-03-01
COMPLETED
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate HypertensionNCT00867490 · lead sponsor · 2009-03-01
COMPLETED
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by MonotherapyNCT01241487 · lead sponsor · 2009-02-01
COMPLETED
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During ExerciseNCT00819767 · lead sponsor · 2009-02-01
COMPLETED
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00856193 · lead sponsor · 2009-02-01
COMPLETED
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 HypertensionNCT00853957 · lead sponsor · 2009-02-01
COMPLETED
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With HypertensionNCT00817414 · lead sponsor · 2009-01-14
COMPLETED
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 HypertensionNCT00809926 · lead sponsor · 2009-01-01
COMPLETED
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe HypertensionNCT00841672 · lead sponsor · 2009-01-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionNCT00817635 · lead sponsor · 2008-12-22
COMPLETED
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyNCT00822211 · lead sponsor · 2008-12-01
COMPLETED
Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma PatientsNCT00814216 · lead sponsor · 2008-12-01
COMPLETED
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 DiabetesNCT00821977 · lead sponsor · 2008-11-01
COMPLETED
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic HypertensionNCT00797316 · lead sponsor · 2008-11-01
COMPLETED

Drugs studied in this sponsor's trials

155 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Novartis as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo73
aliskiren54
vildagliptin41
valsartan35
zoledronic acid24
everolimus20
amlodipine19
letrozole17
placebo RxCUI 8375 · Lead sponsor in 54 linked trial(s) · 1 currently recruiting 73 trials aliskiren RxCUI 325646 · Lead sponsor in 50 linked trial(s) · 0 currently recruiting 54 trials vildagliptin RxCUI 596554 · Lead sponsor in 38 linked trial(s) · 0 currently recruiting 41 trials valsartan RxCUI 69749 · Lead sponsor in 34 linked trial(s) · 0 currently recruiting 35 trials zoledronic acid RxCUI 77655 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 24 trials everolimus RxCUI 141704 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 20 trials amlodipine RxCUI 17767 · Lead sponsor in 17 linked trial(s) · 0 currently recruiting 19 trials letrozole RxCUI 72965 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 17 trials hydrochlorothiazide RxCUI 5487 · Lead sponsor in 15 linked trial(s) · 0 currently recruiting 15 trials ribociclib RxCUI 1873916 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 14 trials docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 12 trials indacaterol RxCUI 1114326 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 12 trials fulvestrant RxCUI 282357 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 11 trials omalizumab RxCUI 302379 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 10 trials lutetium Lu 177 vipivotide tetraxetan RxCUI 2597053 · Lead sponsor in 0 linked trial(s) · 4 currently recruiting 8 trials paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 7 trials trastuzumab RxCUI 224905 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 7 trials canakinumab RxCUI 853491 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 6 trials imatinib mesylate RxCUI 284924 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 6 trials lapatinib RxCUI 480167 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 6 trials alpelisib RxCUI 2169285 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 5 trials carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 5 trials fingolimod RxCUI 1012892 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials prednisone RxCUI 8640 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 5 trials

Sponsor roles

lead sponsor343
collaborator288
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.